A panel discussion during the JPMorgan conference earlier this month examined where oncology drug development is headed, driven in part by advances in diagnostic testing.
Mary Caffrey
Advertisement
Mary Caffrey is the Executive Editor for The American Journal of Managed Care® (AJMC®). She joined AJMC® in 2013 and is the primary staff editor for Evidence-Based Oncology, the multistakeholder publication that reaches 22,000+ oncology providers, policy makers and formulary decision makers. She is also part of the team that oversees speaker recruitment and panel preparations for AJMC®'s premier annual oncology meeting, Patient-Centered Oncology Care®. For more than a decade, Mary has covered ASCO, ASH, ACC and other leading scientific meetings for AJMC readers.
Mary has a BA in communications and philosophy from Loyola University New Orleans. You can connect with Mary on LinkedIn.
Articles by Mary Caffrey
The renewal for the ninth straight year includes McKesson's latest measure for resolution of health-related social needs.
DeepScribe's technology aims to free doctors to focus on the patient visit.
Charleston Area Medical Center (AMC) Vandalia Health was among 3 participants in the Association of Cancer Care Centers' Quality Improvement Program for myeloproliferative neoplasms.
Besides Kent Hospital, the Association of Cancer Care Centers worked with Perlmutter Cancer Center at NYU Langone Hospital and Charleston Area Medical Center Vandalia Health in Charleston, West Virginia.
Perlmutter Cancer Center at NYU Langone was 1 of 3 sites to take part in the Association of Cancer Care Centers quality improvement initiative in myeloproliferative neoplasms (MPNs).
If the subcutaneous delivery method gains approval, an advantage daratumumab holds over isatuximab would be removed.
For several years, investigators have been studying combinations that include ruxolitinib, sold as Jakafi, to treat myeloproliferative neoplasms (MPNs).
Nicole Grieselhuber, MD, PhD, of The Ohio State University, discusses results from Part D of a dosing study involving patients with previously untreated higher-risk myelodysplastic syndrome (MDS) who were treated with a combination of SEA-CD70 and azacitidine.
This interview will appear in the January 2025 issue of Evidence-Based Oncology, our annual recap of the American Society of Hematology Meeting and Exposition. After this article went to press, the company announced its ticker symbol on the Nasdaq will change January 2, 2025.
Prior authorization, PBM reform, and payment for patient navigation were topics of the most popular articles in EBO in 2024.
Articles on myeloproliferative neoplasms (MPNs) covered the debate over how early to use cytoreductive therapies instead of phlebotomy in younger patients with polycythemia vera, the promise of vaccines, and the unmet potential of pegylated interferons.
Haydar Frangoul, MD, MS, medical director, Pediatric Hematology/Oncology for Sarah Cannon Research Institute at TriStar Centennial Children’s Hospital, Nashville, presented the data on the long-term efficacy and safety for participants with sickle cell disease (SCD) who received exa-cel.
The American Society of Hematology is launching a health equity effort, "Treating Fairly," which was discussed at the quality symposium at the 66th Annual Meeting & Exposition.
Results of a small study presented at the 66th American Society of Hematology Annual Meeting & Exposition suggest combining the bispecific elranatamab with the proteasome inhibitor carfilzomib can bring responses even in patients with stage III disease.
The investigational oral HER2-specific tyrosine kinase inhibitor would address an unmet need in non–small cell lung cancer.
The study is the first to evaluate a fixed-duration regimen of venetoclax, the first-generation BCL2 inhibitor, with a second-generation Bruton tyrosine kinase inhibitor, acalabrutinib, in chronic lymphocytic leukemia (CLL).
Research presented at the 66th American Society of Hematology Annual Meeting revealed that a genetic variant enriched in Andean populations, associated with reduced inflammation and improved response to ropeginterferon-α, could guide more precise treatments for polycythemia vera (PV) and essential thrombocythemia.
The inMIND trial was the first to examine dual targeting of CD19 and CD20 in follicular lymphoma.
Abstracts presented Saturday at the American Society of Hematology in San Diego, California, included studies on access to care and an analysis of young physicians' relocation patterns as they transition to fellowship and attending positions.
One of the study’s bright spots is that Hispanic children, who have higher rates of B-cell acute lymphoblastic leukemia and worse outcomes, had proportionally greater benefit from blinatumomab.
The 66th American Society of Hematology (ASH) Annual Meeting & Exposition will take place December 7-10, 2024, in San Diego, California.
A decade after the discovery of CALR, the results are the first for a possible therapy for CALR-mutated MPNs to reach the clinic.
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
New Partnership Model Boosts Maternal Outcomes in Medicaid ACOs
2
Value-Based Care Interventions and Management of CKD Progression
3
Better Food, Better Health: Redefining Chronic Disease Care Through Nutrition
4
CAR T-Cell Therapy Holds Potential in SCLC, but Significant Barriers Remain
5
